[go: up one dir, main page]

MX2007002883A - Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo. - Google Patents

Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.

Info

Publication number
MX2007002883A
MX2007002883A MX2007002883A MX2007002883A MX2007002883A MX 2007002883 A MX2007002883 A MX 2007002883A MX 2007002883 A MX2007002883 A MX 2007002883A MX 2007002883 A MX2007002883 A MX 2007002883A MX 2007002883 A MX2007002883 A MX 2007002883A
Authority
MX
Mexico
Prior art keywords
humanized antibodies
west nile
nile virus
wnv
compositions
Prior art date
Application number
MX2007002883A
Other languages
English (en)
Inventor
Leslie S Johnson
Ling Huang
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2007002883A publication Critical patent/MX2007002883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con composiciones que comprenden anticuerpos humanizados o fragmentos de los mismos que se unen de manera inmunoespecifica a uno o mas antigenos de un flavivirus, particularmente del virus del nilo occidental (WNV), y metodos para evitar, tratar o disminuir los sintomas relacionados con un flavivirus, particularmente con la infeccion por el virus de nilo accidental (WNV) utilizando dichas composiciones. En particular, la presente invencion se relaciona con metodos para evitar, tratar o disminuir en un sujeto humano una cantidad eficaz de uno o mas anticuerpos humanizados o fragmentos de los mismos que se unen de manera inmunoespecifica a un antigeno WNV. La presente invencion tambien se relaciona con composiciones detectables o de diagnostico que comprenden anticuerpos humanizados o fragmentos de los mismos que se unen inmunoespecificamente a un antigeno WNV y metodos para detectar o diagnosticar infeccion por WNV utilizando dichas composiciones.
MX2007002883A 2004-09-13 2005-09-13 Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo. MX2007002883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60976604P 2004-09-13 2004-09-13
PCT/US2005/032587 WO2006031825A2 (en) 2004-09-13 2005-09-13 Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof

Publications (1)

Publication Number Publication Date
MX2007002883A true MX2007002883A (es) 2007-06-15

Family

ID=36060647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002883A MX2007002883A (es) 2004-09-13 2005-09-13 Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.

Country Status (5)

Country Link
US (3) US7572456B2 (es)
CA (1) CA2579142A1 (es)
IL (1) IL181477A0 (es)
MX (1) MX2007002883A (es)
WO (1) WO2006031825A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US7572456B2 (en) * 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EP1915395A2 (en) * 2005-07-25 2008-04-30 Avianax, Inc. Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
US8877187B2 (en) * 2005-07-25 2014-11-04 Avianax, Llc Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
KR101379568B1 (ko) * 2005-08-26 2014-04-08 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
KR101508390B1 (ko) * 2006-06-06 2015-04-08 크루셀 홀란드 비.브이. 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
EP2474322A1 (en) * 2007-04-12 2012-07-11 Omrix Biopharmaceuticals Ltd. Products for prophylaxis and/or treatment of viral diseases and method of making and using same
US20090098143A1 (en) * 2007-06-29 2009-04-16 Avianax, Inc. Vaccine production for pathogenic bird viral diseases
AU2008270972B2 (en) 2007-07-02 2013-10-24 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
DK2464657T3 (en) 2009-08-10 2015-06-29 Morphosys Ag New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
US9499608B2 (en) 2011-06-08 2016-11-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015113055A2 (en) 2014-01-27 2015-07-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ade) of infection
CA2958144A1 (en) * 2014-08-15 2016-02-18 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016176212A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Engineered human anti-aav antibodies and uses thereof
CN105087500A (zh) * 2015-09-07 2015-11-25 江南大学 一株利巴韦林单克隆抗体杂交瘤细胞株及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
CN109069640B (zh) 2016-03-14 2023-10-03 中外制药株式会社 用于癌症治疗的诱导细胞损伤的治疗药物
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
FR3061716B1 (fr) * 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
WO2020023841A1 (en) * 2018-07-27 2020-01-30 Massachusetts Institute Of Technology Oligomerized protein-polymer conjugates
TWI841810B (zh) * 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN112159470B (zh) * 2020-10-09 2021-12-10 中国人民解放军军事科学院军事医学研究院 一种抗wnv感染的结合分子
CN112574298B (zh) * 2020-10-09 2021-08-10 中国人民解放军军事科学院军事医学研究院 一种抗西尼罗河病毒的人源中和性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372711A4 (en) * 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
EP1778879A4 (en) 2004-06-21 2010-02-24 Univ Washington ANTIBODIES TO WEST NIL VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF
US7572456B2 (en) * 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
US7498419B2 (en) 2004-10-14 2009-03-03 Washington University Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody

Also Published As

Publication number Publication date
US20120070429A1 (en) 2012-03-22
US20090324593A1 (en) 2009-12-31
WO2006031825A3 (en) 2006-09-08
CA2579142A1 (en) 2006-03-23
US20060057149A1 (en) 2006-03-16
US7572456B2 (en) 2009-08-11
IL181477A0 (en) 2007-07-04
WO2006031825A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
MX2007002883A (es) Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
WO2005122741A3 (en) Antibodies against west nile virus and therapeutic and prophylactic uses thereof
BRPI0606148A2 (pt) anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus
WO2005115452A3 (en) Fcϝriib-specific antibodies and methods of use thereof
CY1118098T1 (el) Fc riib-ειδικα αντισωματα και μεθοδοι χρησης αυτων
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
BRPI0513798A (pt) anticorpos anti-cd154
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
UA97943C2 (ru) Вакцина против инфекции chlamydia
WO2003104273A3 (en) THERAPEUTIC EPITOPES AND THEIR USES
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
WO2008073312A3 (en) Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
EP2027874A3 (en) Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2005016132A3 (en) Diagnostics for sars virus
DK1476468T3 (da) Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
Wong et al. Prevention of hepatocellular carcinoma: a concise review of contemporary issues

Legal Events

Date Code Title Description
FG Grant or registration